Development of MRC Centre MRI calf muscle fat fraction protocol as a sensitive outcome measure in Hereditary Sensory Neuropathy Type 1 by Kugathasan, Umaiyal et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Development of MRC Centre MRI calf muscle fat fraction protocol as a
sensitive outcome measure in Hereditary Sensory Neuropathy Type 1
Kugathasan, Umaiyal; Evans, Matthew R B; Morrow, Jasper M; Sinclair, Christopher D J; Thornton,
John S; Yousry, Tarek A; Hornemann, Thorsten; Suriyanarayanan, Saranya; Owusu-Ansah, Khadijah;
Lauria, Giuseppe; Lombardi, Raffaella; Polke, James M; Wilson, Emma; Bennett, David L H; Houlden,
Henry; Hanna, Michael G; Blake, Julian C; Laura, Matilde; Reilly, Mary M
Abstract: OBJECTIVES Hereditary sensory neuropathy type 1 (HSN1) is a rare, slowly progressive
neuropathy causing profound sensory deficits and often severe motor loss. L-serine supplementation is
a possible candidate therapy but the lack of responsive outcome measures is a barrier for undertaking
clinical trials in HSN1. We performed a 12-month natural history study to characterise the phenotype of
HSN1 and to identify responsive outcome measures. METHODS Assessments included Charcot-Marie-
Tooth Neuropathy Score version 2 (CMTNSv2), CMTNSv2-Rasch modified, nerve conduction studies,
quantitative sensory testing, intraepidermal nerve fibre density (thigh), computerised myometry (lower
limbs), plasma 1-deoxysphingolipid levels, calf-level intramuscular fat accumulation by MRI and patient-
based questionnaires (Neuropathic Pain Symptom Inventory and 36-Short Form Health Survey version
2 [SF-36v2]). RESULTS 35 patients with HSN1 were recruited. There was marked heterogeneity in
the phenotype mainly due to differences between the sexes: males generally more severely affected. The
outcome measures that significantly changed over 1 year and correlated with CMTNSv2, SF-36v2-physical
component and disease duration were MRI determined calf intramuscular fat accumulation (mean change
in overall calf fat fraction 2.36%, 95% CI 1.16 to 3.55, p=0.0004), pressure pain threshold on the hand
(mean change 40 kPa, 95% CI 0.7 to 80, p=0.046) and myometric measurements of ankle plantar flexion
(median change -0.5 Nm, IQR -9.5 to 0, p=0.0007), ankle inversion (mean change -0.89 Nm, 95% CI -1.66
to -0.12, p=0.03) and eversion (mean change -1.61 Nm, 95% CI -2.72 to -0.51, p=0.006). Intramuscular
calf fat fraction was the most responsive outcome measure. CONCLUSION MRI determined calf muscle
fat fraction shows validity and high responsiveness over 12 months and will be useful in HSN1 clinical
trials.
DOI: https://doi.org/10.1136/jnnp-2018-320198
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-171620
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution-NonCommercial 4.0 International
(CC BY-NC 4.0) License.
Originally published at:
Kugathasan, Umaiyal; Evans, Matthew R B; Morrow, Jasper M; Sinclair, Christopher D J; Thornton,
John S; Yousry, Tarek A; Hornemann, Thorsten; Suriyanarayanan, Saranya; Owusu-Ansah, Khadijah;
Lauria, Giuseppe; Lombardi, Raffaella; Polke, James M; Wilson, Emma; Bennett, David L H; Houlden,
Henry; Hanna, Michael G; Blake, Julian C; Laura, Matilde; Reilly, Mary M (2019). Development of
MRC Centre MRI calf muscle fat fraction protocol as a sensitive outcome measure in Hereditary Sensory
Neuropathy Type 1. Journal of Neurology, Neurosurgery, and Psychiatry, 90(8):895-906.
DOI: https://doi.org/10.1136/jnnp-2018-320198
2
895Kugathasan U, et al. J Neurol Neurosurg Psychiatry 2019;90:895–906. doi:10.1136/jnnp-2018-320198
ReseaRch papeR
Development of MRC Centre MRI calf muscle fat 
fraction protocol as a sensitive outcome measure in 
Hereditary Sensory Neuropathy Type 1
Umaiyal Kugathasan,   1 Matthew R B evans,1,2 Jasper M Morrow,1,2 
christopher D J sinclair,1,2 John s Thornton,1,2 Tarek a Yousry,1,2 Thorsten hornemann,3 
saranya suriyanarayanan,3 Khadijah Owusu-ansah,4 Giuseppe Lauria,5,6 
Raffaella Lombardi,5 James M polke,7 emma Wilson,1 David L h Bennett,8 
henry houlden,1 Michael G hanna,1 Julian c Blake,1,9 Matilde Laura,1 Mary M Reilly   1
Neuromuscular
To cite: Kugathasan U, evans 
MRB, Morrow JM, et al. J 
Neurol Neurosurg Psychiatry 
2019;90:895–906.
For numbered affiliations see 
end of article.
Correspondence to
professor Mary M Reilly, MRc 
centre for Neuromuscular 
Diseases, UcL Institute of 
Neurology and National 
hospital for Neurology and 
Neurosurgery, London Wc1N 
3BG, UK;  m. reilly@ ucl. ac. uk
Received 13 December 2018
Revised 19 February 2019
accepted 21 February 2019
published Online First 17 april 
2019
© author(s) (or their 
employer(s)) 2019. No 
commercial re-use. see rights 
and permissions. published 
by BMJ.
AbsTrACT
Objectives hereditary sensory neuropathy type 1 
(hsN1) is a rare, slowly progressive neuropathy causing 
profound sensory deficits and often severe motor loss. 
L-serine supplementation is a possible candidate therapy 
but the lack of responsive outcome measures is a barrier 
for undertaking clinical trials in hsN1. We performed 
a 12-month natural history study to characterise the 
phenotype of hsN1 and to identify responsive outcome 
measures.
Methods assessments included charcot-Marie-Tooth 
Neuropathy score version 2 (cMTNsv2), cMTNsv2-
Rasch modified, nerve conduction studies, quantitative 
sensory testing, intraepidermal nerve fibre density 
(thigh), computerised myometry (lower limbs), plasma 
1-deoxysphingolipid levels, calf-level intramuscular fat 
accumulation by MRI and patient-based questionnaires 
(Neuropathic pain symptom Inventory and 36-short Form 
health survey version 2 [sF-36v2]).
results 35 patients with hsN1 were recruited. There 
was marked heterogeneity in the phenotype mainly 
due to differences between the sexes: males generally 
more severely affected. The outcome measures that 
significantly changed over 1 year and correlated with 
cMTNsv2, sF-36v2-physical component and disease 
duration were MRI determined calf intramuscular fat 
accumulation (mean change in overall calf fat fraction 
2.36%, 95% cI 1.16 to 3.55, p=0.0004), pressure pain 
threshold on the hand (mean change 40 kpa, 95% cI 0.7 
to 80, p=0.046) and myometric measurements of ankle 
plantar flexion (median change −0.5 Nm, IQR −9.5 to 
0, p=0.0007), ankle inversion (mean change −0.89 Nm, 
95% cI −1.66 to −0.12, p=0.03) and eversion (mean 
change −1.61 Nm, 95% cI −2.72 to −0.51, p=0.006). 
Intramuscular calf fat fraction was the most responsive 
outcome measure.
Conclusion MRI determined calf muscle fat fraction 
shows validity and high responsiveness over 12 months 
and will be useful in hsN1 clinical trials.
INTrOduCTION
Hereditary sensory neuropathy type 1 (HSN1), due to 
SPTCL1 and SPTLC2 gene mutations, is an autosomal 
dominant sensory predominant neuropathy.1 Painless 
slowly healing ulcers, which can lead to osteomyelitis 
and amputations, are frequent. Motor involvement 
is variable1 and neuropathic pain is common.2 As 
a result of a founder mutation in the UK, SPTLC1 
(C133W) is the most common mutation.3
SPTLC1 and SPTLC2 encode for two subunits of 
the enzyme serine palmitoyltransferase (SPT) which 
catalyses the rate-limiting step in de novo sphin-
golipid biosynthesis. SPTLC1 and SPTLC2 muta-
tions alter the substrate specificity resulting in the 
production of 1-deoxysphingolipids (1-deoxySL) 
which have been shown to be neurotoxic in chick 
primary dorsal root ganglion and motor neuron 
cultures.4 Both transgenic mice expressing mutant 
SPTLC1 and patients with HSN1 have elevated 
plasma levels of 1-deoxySLs.4 5 A study using trans-
genic mice expressing mutant SPTLC1 has demon-
strated a mild beneficial treatment effect with oral 
L-serine.6 In the same study, a 10-week pilot trial 
of L-serine in patients with HSN1 showed that 
L-serine was well tolerated and led to a reduction 
in plasma 1-deoxySL levels.
A small (18 patients) randomised placebo-con-
trolled trial in HSN1 which has just been published 
has shown that oral L-serine treatment potentially 
slows disease progression.7 A larger definitive 
efficacy trial of serine in the HSN1 population is 
warranted, however the major barrier is the lack 
of natural history data and responsive outcome 
measures.
Difficulties in conducting clinical trials due to 
the lack of responsive outcome measures in slowly 
progressive inherited neuropathies have been 
highlighted in ascorbic acid trials in Charcot-Ma-
rie-Tooth disease 1A (CMT1A).8–12 In addition to 
failing to detect any benefit with ascorbic acid, 
the studies demonstrated no significant changes in 
their primary outcome measures over 2 years, and 
negligible to small responsiveness of the secondary 
outcome measures.
We recently demonstrated that MRI quantifica-
tion of calf intramuscular fat shows high respon-
siveness over 12 months in patients with CMT1A.13 
These difficulties are compounded in a rare condi-
tion like HSN1 where limited patient numbers 
and phenotypic heterogeneity require even more 
responsive outcome measures.
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To address the lack of natural history data and to develop 
responsive outcome measures, we performed a prospective 
natural history study to extensively characterise the HSN1phe-
notype and identify responsive markers of disease progression 
over 1 year using a variety of tests including MRI.
MATerIAls ANd MeThOds
Patients over the age of 18 with genetically confirmed HSN1 
due to SPTLC1 and SPTLC2 mutations were identified from 
the Neurogenetics Laboratory, National Hospital for Neurology 
and Neurosurgery and Bristol Genetics Laboratory (online 
supplementary figure 1). Exclusion criteria were concomitant 
neuromuscular disease, significant comorbidities including 
medication-dependent diabetes and safety-related MRI contra-
indications. Age and sex-matched control subjects (50% males, 
mean age of males=44.4 years [SD: 7.7, range 36–51], mean age 
of females=41.6 years [SD: 12.6, range 24–57]) were enrolled 
for the MRI (previously validated)13 part of the study to ensure 
any changes noted in the patients were related to disease rather 
than to MRI/technical factors. The healthy controls (no history 
of neuromuscular disorders) were recruited from departmental 
staff and their families.
study design
Patients were assessed at baseline and after 12 months. At the base-
line visit, demographic and clinical information was collected in 
a standardised form. The following assessments were performed 
by a single researcher (UK): Charcot-Marie-Tooth Neuropathy 
Score version 2 (CMTNSv2),14 nerve conduction studies (NCS), 
quantitative sensory testing (QST), computerised myometry and 
skin biopsies. The MRI data were analysed by a single researcher 
(MRBE) who was blinded to diagnosis.
Assessments
Clinical impairment was assessed using the CMTNSv2,14 a 
composite score (0–36 points) of patient symptoms, examina-
tion findings and neurophysiological assessment. The more 
recent Rasch-modified CMTNSv2 (CMTNSv2-R)15 was also 
used, however since it did not have greater sensitivity in picking 
up change, CMTNSv2 measurements are quoted in the results.
NCS were performed using standard techniques.16 Measure-
ments from the right and left sides were averaged to give an 
overall value for each nerve.
QST was performed according to the published protocol of 
the German Research Network on Neuropathic Pain.17 The 
following parameters were tested: cold detection threshold 
(CDT), warm detection threshold (WDT), thermal sensory 
limen (TSL), cold pain threshold (CPT), heat pain threshold 
(HPT), mechanical detection threshold (MDT), mechanical 
pain threshold (MPT), vibration detection threshold (VDT) 
and pressure pain threshold (PPT). Paradoxical heat sensation 
(PHS), mechanical pain sensitivity (MPS), dynamic mechanical 
allodynia (DMA) and wind-up ratio (WUR) were also assessed 
at baseline. QST was also performed on the left trunk area when 
undetectable thermal thresholds were noted in the hands.18 For 
baseline measures, Z-scores were calculated [Z-score=(value of 
patient−mean value of controls)/SD of controls].17
Bilateral lower limb myometry was performed using HUMAC 
NORM dynamometer (CSMi, MA, USA). The protocol13 
included isometric measurements of knee extension and flexion, 
ankle dorsiflexion and plantar flexion, and ankle inversion 
and eversion. Measurements for the right and left sides were 
averaged.
A 3 mm diameter skin punch biopsy was taken on the lateral 
side of the thigh. This site rather than the conventional site of 
distal leg was chosen in accordance with ethical advice due to 
concerns over poor healing and floor effects in patients with this 
length-dependent neuropathy. Specimen processing and quan-
tification of the intraepidermal nerve fibre densities (IENFD) 
were performed in the ‘Carlo Besta’ Neurological Institute, 
Milan, Italy, according to established guidelines.19
Plasma 1-deoxySL levels were analysed at the Institute of 
Clinical Chemistry, University Hospital, Zurich, Switzerland. 
1-deoxySL (1-deoxysphinganine and 1-deoxysphingosine) 
levels were measured as already described20 and compared with 
laboratory controls. Both baseline and follow-up samples were 
analysed together to eliminate interassay variability and were 
calibrated using internal standards.
The Neuropathic Pain Symptom Inventory (NPSI) and SF-36 
(version 2)21 were used to assess pain and quality of life, respec-
tively. Norm-based scoring was used for SF-36 where lower 
scores reflect poorer health status.22
For the MRI, both lower limbs were examined in a 3T MRI 
scanner (TIM Trio, Siemens, Erlangen, Germany). As part of a 
wider protocol, the three-point Dixon technique23 was used for 
fat quantification of the proximal calf muscles with 82×5 mm 
contiguous slices, 512×240 matrix. Individual muscle-group 
regions of interest (ROI) were manually defined by a single 
observer. Bilateral ROIs were defined for seven lower limb 
muscles at a level of 130 mm distal to the tibial plateau: tibi-
alis anterior, extensor hallucis longus, peroneus longus, medial 
gastrocnemius, lateral gastrocnemius, soleus and the deep poste-
rior group. For all individual ROI, custom-written software 
extracted individual muscle-group ROI mean fat fraction (%) 
and cross-sectional area in millimeter squared. Full details of 
acquisition protocol and MRI analysis methods are found in the 
online supplementary method 1.
Right and left leg MRI fat fraction values for each muscle were 
averaged to give an overall mean value per patient. A summary 
measure (‘overall calf muscle fat fraction’) was calculated for 
each participant, representing the mean combined fat fraction 
of all ROI across both lower limbs weighted to cross-sectional 
surface area.
statistical analysis
SPSS statistics V.22 (IBM) and GraphPad Prism V.6 (GraphPad 
Software, La Jolla, California, USA) were used for statistical 
analysis. All data were tested for normality by Shapiro-Wilk test 
in conjunction with visual inspection of frequency distribution 
graphs. For cross-sectional baseline data, mean values/SDs and 
median/IQR are given as appropriate. Mann-Whitney test was 
used for comparison between controls and patients for the MRI 
fat fraction measurements.
Change over 1 year (follow-up minus baseline) was repre-
sented as means/95% CI or medians/IQR (as appropriate). 
Missing data were excluded from the analysis and change was 
only calculated in patients who had both baseline and 12-month 
follow-up data. The significance of mean change was evaluated 
using one-sample two-tailed t-tests (normally distributed) and 
one-sample Wilcoxon signed-rank tests (non-normally distrib-
uted). Statistical significance was set at 5%.
Linear regression was performed to assess the dependence of 
CMTNSv2 on gender and disease duration. Spearman’s rank 
correlation was used to assess correlation between CMTNSv2, 
SF-36v2, disease duration and other tests performed in the 
study. Correlation with plasma 1-deoxySL levels was assessed 
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Table 1 Baseline characteristics:patient demographics and clinical 
history
sPTlC1 sPTlC2
Males Females Males Females
Patients 18 13 2 2
Mutation C133W C133W S384F S384F
A182P
Mean age, years (SD; 
range)
48.9 (13.1; 
23–71)
43.9 
(17.3; 
20–73)
52.5 (49–56) 66.5 (65–68)
Mean disease 
duration, years
(SD; range)
27.2 (14.1; 
7–54)
18.8 
(15.6; 
3–63)
16 (16–16) 36.5 (21–52)
Mean age at onset, 
years
(SD; range)
21.7 (7.2; 
12–37)
25.1 
(14.3; 
10–50)
36.5 (33–40) 30.0 (13–47)
Mean age at first 
ulcer, years
(SD; range)
28.0 (10.9; 
16–63)
28.6 
(15.8; 
10–65)
(n=12)
41
(n=1)
31.5 (13–50)
Mean age at onset 
of neuropathic pain, 
years (SD; range)
30.6 (12.9; 
14–61)
(n=16)
30.8 
(13.4; 
15–52)
(n=12)
40.5 (40–41) 54.0 (53–55)
Complication: 
osteomyelitis
33.3% (6/18) 0% 50.0% (1/2) 0%
Complication: 
amputation
5.6% (1/18) 0% 50.0% (1/2) 50.0% (1/2)
CMTNSv2
(SD; range)
26.8 (5.1; 
16–35)
(n=17)
14.2 
(10.4; 
3–24)
13.5 (5–22) 20.0 (15–25)
CMTNSv2-R
(SD; range)
31.5 (5.9; 
17–39)
16.5 
(12.1; 
4–39)
15.0 (6–24) 24.0 (19–29)
n is the number of patients reporting the specified symptom when different from 
that quoted at the top of the table.
CMTNSv2, Charcot-Marie-Tooth Neuropathy Score version 2; CMTNSv2-R, 
CMTNSv2-Rasch modified.
following normalisation of plasma 1-deoxySL by log transforma-
tion. Statistical significance was set at 0.1% (p<0.001) following 
Bonferroni correction for multiple comparisons.
The standardised response mean (SRM),24 also known as 
Cohen’s d, was used to measure effect size. SRM is an estab-
lished term in this field as a measure of outcome responsiveness 
and will enable comparison between different outcome measures 
within and between studies.13 25 It was calculated by dividing the 
mean change (follow-up - baseline) by the SD. SRMs of 0.20–
0.49, 0.50–0.79 and ≥0.80 reflect small, moderate and large 
responsiveness, respectively.25
resulTs
Between September 2013 and July 2014, a total of 35 patients 
and 10 healthy MRI controls were recruited. The demographic 
and clinical baseline profiles are presented in table 1 and figure 1. 
There was no significant difference in age at baseline between 
males and females.
Loss of sensation (43% of patients) followed by painless foot 
injury (31% of patients) were the most common initial symptoms. 
A greater heterogeneity was seen in SPTLC1 females compared 
with the SPTLC1 males with a larger variation in age of onset 
(range 10–50 years vs 12–37 years [figure 1A]) and disease 
severity (CMTNSv2 range=3–34 vs 16–35 [figure 1B,C]). 
There was also a variation in disease progression within SPTLC1 
females. There was a significant difference (p=0.002) in disease 
severity as determined by the CMTNSv2 between the males and 
females, with males being more severely affected (figure 1C). In 
patients with SPTLC1 (C133W) mutations, gender was a signif-
icant predictor of CMTNSv2 (R2=0.38, ß=−0.63, p<0.001) 
accounting for 40% of the variation seen in CMTNSv2. Disease 
duration accounted for 46% of the variation in CMTNSv2 
(R2=0.44, ß=0.68, p<0.001).
NCS and QST showed a clear length-dependent pattern of 
sensory and motor deficits (table 2, figure 1D–J). QST profiles 
illustrate early small (CDT, WDT) and large fibre (MDT, VDT) 
involvement in HSN1. All the QST parameters showed predom-
inantly a loss of function (negative Z-scores); however, PPT was 
reduced (gain of function) in a subset of patients when tested 
at the hand, trunk and face. The distribution of the abnormal 
PPTs (face>trunk>hands) suggests there might be early hyper-
sensitivity followed by decreased sensitivity as the neuropathy 
progresses. A small number of patients were hyperalgesic with 
increased MPS in the hands (6% [2/35]) and trunk (15% [3/20]). 
None of the patients had allodynia (determined by DMA) or 
increased temporal summation of pain (determined by WUR).
Results of the computerised myometry are summarised in 
table 3. Ankle dorsiflexion was the worst affected with zero 
power detected in 68% (13/19) and 20% (3/15) of male/female 
patients.
Skin biopsy analysis showed complete denervation in 60% 
(12/20) of male patients and 21% (3/14) of female patients 
(figure 2A and table 3). All patients had severely reduced IENFD 
(median 0.1 [IQR=0.0–1.8]) compared with published norma-
tive data26 apart from two patients with the mildest pheno-
type (CMTNSv2 ≤5). Plasma 1-deoxysphinganine levels were 
elevated in all patients compared with laboratory controls. 
There were no significant differences in the plasma 1-deox-
ysphinganine (p=0.17) levels between males and females 
(figure 2B and table 3). In males, plasma 1-deoxysphinganine 
level correlated moderately (rs=0.549, p=0.01) with CMTNSv2 
whereas there was no correlation between plasma 1-deoxysphi-
naganine (rs=0.274, p=0.32) level and CMTNSv2 (figure 2C) 
in females.
The pain profile was similar between males and females 
(figure 2D) with no significant difference (p=0.65) in the total 
NPSI score (table 3). All but one patient had the typical lanci-
nating pain. There was no correlation between total NPSI score 
and plasma 1-deoxysphinganine level (r=−0.02). In the SF-36v2 
for the whole cohort, physical domains had lower scores 
compared with age-matched controls (table 3).
For the MRI assessments, 34 patients with HSN and 10 
controls were analysed at baseline and the results are summarised 
in table 3. Representative images are shown in figure 2E. The 
combined overall muscle and each individual muscle mean fat 
fractions were significantly higher in patients with HSN than 
healthy controls for the whole cohort (p values range=<0.001) 
and when subdivided into gender (p values range=0.001 to 
<0.001 in males, 0.02 to <0.001 in females). Overall calf 
muscle fat fraction correlated strongly with CMTNSv2 in both 
males (rs=0.850, p<0.0001) and females (rs=0.859, p<0.0001) 
(figure 2F). Once there is motor involvement, intramuscular fat 
accumulation progresses similarly between males and females 
(figure 2G).
The outcome measures at baseline were correlated with 
CMTNSv2, disease duration and the physical component of 
the SF-36v2 (SF-36v2PC). The results are listed in the online 
supplementary table 1. Outcome measures that moderately/
strongly correlated with all three correlation variables include 
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Figure 1 patient demographics and baseline cross-sectional data (part 1). (a) Variation in age of onset between male and female patients with SPTLC1 
and SPTLC2 mutations. (B) Disease progression in male and female SPTLC1 and SPTLC2 patients. (c) Tukey box plot showing the distribution of cMTNsv2 
in males and females. There is a significant difference in disease severity between males and females (*p=002, Mann-Whitney test). Box: IQR; horizontal 
line: median; whiskers: 1.5 IQR; blue triangle: major outlier in the male group. (D, e) Large floor effects are seen in the sensory (D) and motor (e) nerve 
conduction studies in the upper limbs in both males and females. (F, G) Quantitative sensory testing (QsT) in feet (F) and hands (G). Most of the responses 
are undetectable/beyond the recordable range. (h–J) somatosensory profiles determined with QsT in the hands (h), face (I) and trunk (J). Data are expressed 
as Z-scores with sDs. Yellow area indicates normal range (95% cI). Z values below ‘0’ indicate loss of function and above ‘0’ indicate gain of function. cDT, 
cold detection threshold; cMap, compound muscle action potential; cMTNsv2, charcot-Marie-Tooth Neuropathy score version 2; cpT, cold pain threshold; 
DMa, dynamic mechanical allodynia; hpT, heat pain threshold; MDT, mechanical detection threshold; Mps, mechanical pain sensitivity; MpT, mechanical pain 
threshold; ppT, pressure pain threshold; sNap, sensory nerve action potential; TsL, thermal sensory limen; VDT, vibration detection threshold; WDT, warm 
detection threshold; WUR, wind-up ratio.
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Table 2 Baseline neurophysiology (nerve conduction studies and quantitative sensory testing)
Nerve conduction studies
All
Median (IQr)
Males
Median (IQr)
Females
Median (IQr)
Ulnar nerve SNAP, μV (IQR) 0.0 (0.0–1.3) 0.0 (0.0–0.0) 1.0 (0.0–7.5)
Radial SNAP, μV (IQR) 0.0 (0.0–6.5) 0.0 (0.0–0.0) 6.0 (0.0–40.0)
Median CMAP, mV (IQR) 3.4 (0.0–6.9) 0.2 (0.0–3.9) 6.9 (2.8–8.1)
Ulnar CMAP, mV (IQR) 2.0 (0.0–7.5) 0.1 (0.0–2.4) 7.2 (2.4–9.6)
Posterior tibial CMAP, mV (IQR) 0.0 (0.0–0.1) 0.0 (0.0–0.0) 0.02 (0.0–0.5)
Common peroneal CMAP, mV (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–1.0)
Quantitative sensory testing (QsT)
 CdT WdT Tsl CPT hPT MdT MPT VdT PPT
Feet All UR (UR to UR) UR (UR to UR) UR (UR to UR) UR (UR to UR) UR (UR to UR) UR (UR to UR) UR (UR to UR) 3.56 (−4.83 to 
−2.73)
UR
(UR to UR)
Male UR (UR to UR) UR (UR to UR) UR (UR to UR) UR (UR to UR) UR (UR to UR) UR
(UR to UR)
UR
(UR to UR)
−4.12 (−6.06 to 
−3.12)
UR
(UR to UR)
Female UR (UR to −8.38) UR
(UR to UR)
UR (−8.12 to UR) UR
(UR to −7.97)
UR
(UR to −1.96)
UR
(UR to UR)
UR
(UR to −3.52)
−3.02 (−3.81 to 
−2.16)
UR (UR to 0.73)
Hand All UR
(UR to −1.36)
UR
(UR to −3.76)
UR
(UR to −2.26)
UR
(UR to −1.3)
UR
(UR to UR)
UR
(UR to
−2.21)
−3.47
(UR to
−1.42)
−3.43
(−5.62 to −2.00)
−0.04
(UR to 1.94)
Male UR
(UR to
−5.20)
UR
(UR to UR)
UR
(UR to
−3.04)
UR
(UR to UR)
−1.69
(UR to 0.1)
UR
(UR to UR)
UR
(UR to
−2.18)
−4.70
(−6.00 to −2.76)
UR
(UR to 0.64)
Female −1.36
(UR to 0.15)
−4.01
(UR to
−1.65)
−2.83
(UR to
–1.14)
−1.62
(UR to
−0.21)
−1.96
(UR to 0.1)
−2.24
(UR to
−0.81)
−1.46
(UR to 0.19)
−2.56
(−5.59 to
−0.38)
1.74
(−2.5 to 3.42)
Trunk All −1.24 (−1.71 to 
−0.49)
−1.59
(−2.81 to
−0.03)
−0.78
(−1.73 to 0.04)
0.48
(−0.54 to 1.45)
−0.02
(−0.54 to 0.81)
−1.56
(−2.13 to
−0.84)
−0.64
(−1.58 to 0.84)
−1.53
(−2.6 to −0.58)
1.55 (0 to 3.07)
Male (n=14–16) −1.15
(−1.65 to
−0.49)
−1.91
(−2.81 to
−0.75)
−0.76
(−2.02 to 0.05)
0.51
(−0.41 to 1.46)
0.25
(−0.36 to 0.87)
−1.37
(−2.08 to
−0.41)
−0.71
(−1.33 to 0.71)
−1.67
(−2.84 to
−1.07)
1.92
(0.15 to 3.85)
Female (n=5) −1.24
(−1.86 to 0.68)
0.31
(−3 to 1.42)
−0.8
(−1.11 to −0.07)
0.48
(−1.26 to 1.12)
−0.91
(−1.07 to 0.80)
−1.70
(−3.77 to −1.14)
−0.20
(−2.63 to 1.41)
−0.80
(−1.77 to
−0.25)
0.73
(−0.85 to 1.15)
Face All 0.04
(−1.45 to 0.68)
−0.66
(−1.26 to 0.44)
−0.23
(−1 to 0.12)
0.88
(0.17 to 1.4)
0.2
(−0.38 to 1.21)
0.65
(−0.51 to 1.92)
1.01
(−0.13 to 1.60)
−1.51 (−2.34 to 
0.05)
2.97
(1.84 to 3.47)
Male −0.27
(−2.15 to 0.27)
−0.85
(−1.38 to −0.01)
−0.46
(−1.04 to −0.06)
0.77
(0.32 to 1.33)
0.41
(−0.19 to 1.46)
0.02
(−2.23 to 0.82)
0.94
(−0.53 to 1.57)
−1.92
(−2.3 to −0.37)
2.60
(1.22 to 3.12)
Female 0.23
(−0.31 to 0.99)
0.18
(−1.15 to 0.93)
−0.09
(−0.42 to 0.29)
1.11
(−0.51 to 1.42)
−0.01
(−0.58 to 1.15)
1.73
(0.50 to 1.92)
1.31
(0.07 to 1.62)
−1.00
(−2.83 to 0.69)
3.45 (2.90 to 
3.52)
QST data are expressed as Z-scores (IQR) where values above 2 represent abnormal gain of function and values below −2 represent abnormal loss of function. In the trunk, n is the number of patients tested.
CDT, cold detection threshold; CMAP, compound muscle action potential; CPT, cold pain threshold; HPT, heat pain threshold; LL, lower limb; MDT, mechanical detection threshold; MPT, mechanical pain threshold; PPT, 
pressure pain threshold; SNAP, sensory nerve action potential; TSL, thermal sensory limen; UR, unrecordable; VDT, vibration detection threshold; WDT, warm detection threshold.
NCS, QST-Hand, isometric ankle dorsiflexion/plantar flexion/
inversion/eversion and calf muscle fat fraction.
Change over 12 months
Three patients were lost to follow-up (online supplemen-
tary figure 1). Follow-up assessments were done after 1 year 
(mean=364 days±7 days). Detailed results are summarised in 
tables 4 and 5. There was no significant change in the CMTNSv2, 
CMTNSv2-R, NCS, IENFD, NPSI or SF-36v2 over 12 months. 
Plasma 1-deoxysphinganine levels significantly decreased over 
1 year (mean change −0.13 µM, 95% CI −0.24 to −0.02, 
p=0.02).
In QST, significant changes reflecting clinical deterioration 
were only seen in Hand-PPT (p=0.04), Face-VDT (p=0.04) and 
Face-PPT (p<0.0001). Significant deterioration was noted in 
ankle plantar flexion (p=0.0007), ankle inversion (p=0.03) and 
ankle eversion (p=0.006) (table 5).
For MRI, 25 patients with HSN and 10 controls were 
analysed at 12 months (table 5 and figure 2H). Other than 
the three patients lost to follow-up, other data are ‘missing 
completely at random’ due to technical reasons with the 
MRI or data transfer. There were significant increases in all 
the individual calf muscle fat fractions and the overall calf 
muscle fat fraction (p values range=0.03 to <0.0001) whereas 
there was no significant change in the control group (p values 
range=0.16–0.79).
In summary, calf muscle fat fraction, Hand-PPT and isometric 
ankle plantar flexion, inversion and eversion significantly 
changed over 12 months and correlated with CMTNSv2, 
SF36-v2PC and disease duration. Their relative responsiveness 
(SRMs) are shown in table 6. Calf muscle fat fraction had the 
best responsiveness both in individual muscles and as overall 
calf muscle fat fraction (overall calf muscle fat fraction SRM 
0.81 vs SRM of 0.49 for Hand-PPT and SRM <0.40 for myom-
etry). Overall calf muscle fat fraction changes were smaller in 
patients with baseline fat fraction less than 5% or greater than 
70% (figure 2H). All patients with overall calf muscle fat frac-
tion less than 5% had CMTNSv2 of 10 or less. Patients with fat 
fraction greater than 70% had CMTNSv2 ranging from 28 to 
34. Focusing on the patients with baseline overall calf muscle fat 
fraction of 5%–70% (20 patients, 59% of MRI cohort) mark-
edly improved the responsiveness (overall calf muscle fat frac-
tion SRM of 1.60).
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Table 3 Baseline measures for computerised myometry, intraepidermal nerve fibre density, plasma deoxysphingolipid levels, SF-36v2 scores and 
calf muscle fat fraction
All
Median (IQr)
Males
Median (IQr)
Females
Median (IQr)
Myometric measurements
  Isometric ankle dorsiflexion (Nm) 0 (0–18) 0 (0–3) 10 (0–23)
  Isometric ankle plantar flexion (Nm) 7 (0–25) 2 (0–18) 20 (1–27)
  Isometric ankle inversion (Nm) 5 (0–14) 4 (0–14) 5 (2–14)
  Isometric ankle eversion (Nm) 4 (0–12) 2 (0–9) 6 (1–14)
  Isometric knee extension (Nm) 100 (63–137) 132 (66–152) 86 (63–100)
  Isometric knee flexion (Nm) 51 (32–71) 64 (31–76) 45 (32–55)
Intraepidermal nerve fibre density (IENFD)
  IENFD (fibres/mm) 0.1 (0.0–1.8) 0.0 (0.0–1.3) 1.2 (0.1–2.7)
Plasma deoxysphingolipids
  1-Deoxysphinganine (μM) 0.79 (0.49–1.03) 0.94 (0.50–1.23) 0.54 (0.32–0.99)
  1-Deoxysphingosine (μM) 1.5 (0.96–2.40) 1.68 (1.18–2.48) 1.13 (0.80–2.18)
Neuropathic Pain Symptom Inventory (NPSI)
  Total NPSI score (0–100) 25 (14–37) 23.5 (15–40) 22.0 (13–36)
  Paroxysmal subscore (0–10) 5 (3–8) 6 (3–8) 5 (2–7)
SF-36v2
  Physical component score 37.5 (33.5–49.8) 34.8 (31.9–40.2) 51.4 (36.6–55.9)
  Mental component score 53.6 (44.8–59.3) 51.4 (43.9–58.6) 54.3 (46.4–59.9)
  Physical functioning 34.6 (26.9–53.7) 30.8 (54.0–41.3) 44.2 (32.7–57.5)
  Role-physical 47.1 (34.1–57.2) 39.2 (32.5–51.5) 57.2 (45.9–57.2)
  Bodily pain 42.2 (38.2–50.7) 43.0 (8.1) 45.0 (12.3)
Calf muscle fat fraction
 
All
hsN1 group
Median FF% (IQr)
All Control group
Median FF% (IQr) P value
hsN1 Males
Median FF%
(IQr)
Control Males
Median FF% (IQr) P value
hsN1 Females
Median FF% 
(IQr)
Control Females 
Median FF%
(IQr) P value
Tibialis anterior 13.1 (2.9–41.9) 0.8 (0.7–1.8) <0.0001 14.3 (4.9–41.1) 0.9 (0.7–2.1) 0.0002 12.0 (1.4–44.3) 0.8 (0.7–1.3) 0.02
Extensor hallucis longus 16.8 (3.3–57.3) 1.3 (1.0–1.9) <0.0001 17.8 (10.6–59.8) 1.9 (1.1–3.4) 0.0009 16.0 (1.6–54.7) 1.2 (1.0–1.4) 0.0003
Peroneus longus 26.2 (4.8–64.3) 1.6 (1.2–2.2) <0.0001 37.0 (18.3–69.3) 2.2 (1.7–4.4) 0.0002 9.9 (2.6–60.5) 1.2 (1.1–1.7) 0.0004
Soleus 24.4 (4.8–63.2) 1.6 (1.1–2.6) <0.0001 28.0 (11.4–75.6) 2.0 (1.4–6.9) 0.001 5.7 (2.0–56.6) 1.3 (1.1–1.8) 0.003
Lateral gastrocnemius 37.1 (4.5–79.8) 1.2 (1.2–2.4) <0.0001 32.4 (11.5–78.1) 1.2 (1.1–4.0) 0.0006 49.7 (2.0–82.5) 1.3 (1.1–2.1) 0.005
Medial gastrocnemius 33.9 (4.2–71.8) 1.4 (1.0–2.8) <0.0001 34.3 (14.0–79.1) 1.7 (1.3–6.4) 0.0003 3.0 (1.3–52.5) 1.0 (0.9–1.7) 0.02
Deep posterior group 13.6 (2.5–52.4) 1.3 (1.1–1.6) <0.0001 15.7 (9.2–54.0) 1.6 (1.1–3.1) 0.0002 1.8 (1.6–36.3) 1.2 (1.1–1.3) 0.0005
Combined overall 22.3 (5.9–59.6) 1.3 (1.1–1.9) <0.0001 22.7 (9.6–66.6) 1.5 (1.3–5.3) 0.0002 14.7 (1.6–58.7) 1.1 (1.1–1.5) 0.001
Baseline measures are given as medians (IQR).
FF%, fat fraction percentage; HSN1, hereditary sensory neuropathy type 1; SF-36v2, 36-Short Form Health Survey version 2 (1998).
dIsCussION
In this study we describe the baseline characteristics and 
12-month follow-up of a cohort of patients with HSN1 with 
SPTLC1 and SPTLC2 gene mutations. This is the first study to 
analyse intramuscular fat accumulation as a potential outcome 
measure in patients with HSN1.
In our baseline analysis, this study highlights the large pheno-
typical heterogeneity in SPTLC1 patients with HSN1 in the UK 
harbouring the same mutation (C133W). This heterogeneity 
was largely due to the differences in severity between males and 
females, where males were generally more severely affected. 
The significant difference in clinical severity, determined with 
the CMTNSv2, between males and females cannot be attributed 
to differences in plasma deoxysphingolipid levels which were 
not significantly different between the two sexes. Within the 
SPTLC1 female subgroup, there appeared to be phenotypic spec-
trum with females who have age of onset and disease progression 
similar to males and females with late onset and much slower 
rate of progression.
Dissociated sensory loss where nociception and temperature 
sensation (small fibre involvement) are affected early and more 
severely compared with vibration and proprioception (large 
fibre involvement) is well documented in HSN1.1 2 QST profiles 
demonstrate that there is also early large fibre involvement with 
deficits in mechanical perception mirroring that of tempera-
ture perception. We noted, as previously reported,27 an initial 
period of hypersensitivity to noxious pressure (lowered PPTs) 
and hyperalgesia (increased MPS). Despite the name, prominent 
motor involvement was seen in both male and female patients. 
We had previously used the same computerised myometry 
protocol that was used in this study to assess plantar flexion and 
dorsiflexion strengths in patients with CMT1A with ages similar 
to that of our cohort of patients with HSN1.13 On comparing 
the two groups, the patients with HSN1 had much greater 
motor impairment: mean isometric plantar flexion was 26.0 Nm 
(SD=14.3) and dorsiflexion was 10.8 Nm (SD=7.5) in patients 
with CMT1A versus median isometric plantar flexion of 7 Nm 
(IQR=0–25) and dorsiflexion of 0 Nm (IQR=0–18) in patients 
with HSN1.
For our longitudinal study we used a comprehensive range 
of measures including clinical, neurophysiological, myometric, 
plasma 1-deoxySL levels, IENFD and MRI measurement of calf 
intramuscular fat accumulation. To determine the validity of the 
outcome measures, the measures were correlated with a clinical 
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Figure 2 Baseline cross-sectional data (part 2) and MRI characteristics. (a) Distribution of intraepidermal nerve fibre density (IeNFD) measures in males 
and females. (B) Distribution of plasma 1-deoxysphinganine levels in males and females. (c) correlation between cMTNsv2 and plasma 1-deoxysphinganine. 
(D) Neuropathic pain symptom Inventory (NpsI) profiles in males and females. solid bar: median. (e) Fat fraction map of a control male subject, mildly 
affected (cMTNsv2=5), moderately affected (cMTNsv2=16) and severely affected (cMTNsv2=34) male patients with hereditary sensory neuropathy type 1 
(hsN1). (F) correlation between overall calf muscle fat fraction and cMTNsv2. (G) change in overall calf muscle fat fraction with duration of lower limb (LL) 
motor symptoms in males and females. (h) Degree of change in overall calf muscle fraction over 1 year depends on its baseline value. cMTNsv2, charcot-
Marie-Tooth Neuropathy score version 2.
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Table 6 Responsiveness of tests which had a significant change over 12 months
Mean change (95% CI) srM P value
Quantitative sensory testing
Hand-PPT (kPa) 40 (0.7 to 80) 0.49 0.046
Computerised myometry
Isometric ankle plantar flexion (Nm) −0.50* (−9.5 to 0) na 0.0007
Isometric ankle inversion (Nm) −0.89 (−1.66 to −0.12) −0.33 0.03
Isometric ankle eversion (Nm) −1.61 (−2.72 to −0.51) −0.40 0.006
Calf muscle fat fraction
Tibialis anterior (FF%) 2.03 (0.72 to 3.33) 0.64 0.004
Extensor hallucis longus (FF%) 2.93 (1.50 to 4.37) 0.84 0.0003
Peroneus longus (FF%) 2.35 (1.22 to 3.48) 0.86 0.0002
Soleus (FF%) 1.75 (0.66 to 2.84) 0.66 0.003
Lateral gastrocnemius (FF%) 2.46* (−0.12 to 6.87) na 0.003
Medial gastrocnemius (FF%) 1.68* (0.10 to 5.49) na <0.0001
Deep posterior group (FF%) 2.51 (0.99 to 4.02) 0.68 0.002
Overall calf muscle (FF%) 2.36 (1.16 to 3.55) 0.81 0.0004
MrI proximal calf fat fraction in subgroup with baseline overall calf FF=5%–70%
Tibialis anterior (FF%) 3.98 (2.37 to 5.59) 1.49 0.0002
Extensor hallucis longus (FF%) 4.94 (2.70 to 7.19) 1.33 0.0004
Peroneus longus (FF%) 4.25 (3.01 to 5.48) 2.07 <0.0001
Soleus (FF%) 3.33 (1.62 to 5.04) 1.18 0.001
Lateral gastrocnemius (FF%) 4.66 (−0.56 to 9.89) 0.54 0.08
Medial gastrocnemius (FF%) 6.57 (2.35 to 10.79) 0.94 0.005
Deep posterior group (FF%) 4.91 (3.01 to 6.80) 1.56 0.0001
Overall calf muscle (FF%) 4.34 (2.70 to 5.99) 1.60 <0.0001
Change is reported as mean change unless marked with an asterisk.
*Median change (IQR) is reported.
FF%, fat fraction percentage; HSN1, hereditary sensory neuropathy type 1; PPT, pressure pain threshold; SRM, standardised response mean; na, not applicable as SRM values 
cannot be calculated in cases where the change is not normally distributed.
composite measure of disability, CMTNSv2, a patient self-as-
sessment score, SF36-v2PC and disease duration. Calf muscle 
fat fraction, NCS, QST in the hand and isometric ankle plantar 
flexion, dorsiflexion, inversion and eversion correlated strongly/
moderately with all three validation variables.
Due to the heterogeneity in the cohort, many of the outcome 
measures were limited by both floor and ceiling effects. No 
significant changes were observed for most of the measures over 
12 months and hence cannot be used in an HSN1 clinical trial 
if the aim of the therapy is disease stabilisation. These include 
CMTNSv2, CMTNSv2-R, NCS, IENFD, NPSI and SF-36v2.
A recent randomised, placebo-controlled trial in patients with 
HSN using oral L-serine supplementation by Fridman et al7 did 
not show a significant difference in the primary outcome (propor-
tion of patients progressing more than one point on the CMTNS 
at 1 year) between L-serine and placebo groups. However, it 
showed a decline in CMTNS (−1.5 units, 95% CI −2.8 to 0.1, 
p=0.03) in L-serine participants relative to placebo whereas 
the placebo group experienced a mean increase in CMTNS 
of 1.1 point (±0.53, p=0.04). The difference in the CMTNS 
progression in their placebo group and our study (change in 
CMTNS=0.23, 95% CI−0.24 to 0.68), despite having patients 
with similar distribution of severity (mean CMTNS=24.6 [7.0] 
vs median=22.0 [10–28]), could be secondary to differences in 
sample size. The annual change in CMTNS noted in patients 
with CMT1A ranged from −0.92 to +1.0 unit.8–11 28 This 
variability highlights the limitations of using the CMTNS as a 
primary outcome measure in slowly progressive neuropathies.
Comparable changes over 1 year were noted in NCS and 
SF36v2 between this study and the placebo group of the 
randomised trial.7 Greater within-group variability was seen for 
IENFD (thigh) in the trial. This could reflect differences in tech-
niques used for analysis.
In the current study of the neurophysiological measures, only 
Hand-PPT significantly changed over 12 months and correlated 
strongly with all three validation variables. However, it only has 
small/moderate responsiveness (SRM=0.49) and it is unlikely 
that QST parameters could be used singly as a primary outcome 
measure.
Significant change over 1 year was noted in myometric 
measurements of ankle plantar flexion, ankle inversion and 
ankle eversion; however, ankle inversion and eversion have small 
responsiveness (SRMs <0.40). SRM could not be calculated for 
ankle plantar flexion as the change was not normally distributed 
but if normal distribution was assumed, it would have moderate 
responsiveness with an SRM of 0.62 (mean=−4.5 Nm, 95% CI 
−7.2 to −1.9 Nm). Isometric ankle plantar flexion could there-
fore be explored as a potential secondary outcome measure in 
HSN1.
Surprisingly, a small but significant decrease in the plasma 
1-deoxysphinganine level was found after 1 year. Differences in 
diet (intake of serine and alanine) and technical factors (differ-
ences in number of freeze-thaw cycles, transport time from UK 
to Switzerland) between the two time points could be possible 
explanations. Plasma 1-deoxySL levels have been shown to 
dramatically decrease with L-serine treatment and remain 
suppressed for the duration of treatment.6 7 Therefore, plasma 
1-deoxySL levels are potentially very useful to show compliance 
and target engagement in an L-serine trial aiming at reducing 
these levels but they are unlikely to be useful as a marker of 
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disease stabilisation. It is possible that in the context of neurop-
athy, 1-deoxySL levels in cerebrospinal fluid may be more rele-
vant; however, no studies have investigated this in patients with 
HSN1 .
MRI determined fat quantification using the Dixon method 
has been shown to be reliable, sensitive and responsive as an 
outcome measure in recent natural history studies in various 
neuromuscular disorders.13 29 30 Of all the tests performed, the 
MRI fat fraction quantification is the most promising as an 
outcome measure in HSN1. Despite large heterogeneity in the 
HSN1 group, the changes in both combined overall fat fraction 
and individual muscle fat fraction over 12 months were signif-
icant in patients with HSN1 whereas healthy controls showed 
no significant change. It also showed greater responsiveness 
(overall calf muscle fat fraction SRM 0.81) when compared with 
the other outcome measures in the study (SRM <0.49). In a 
previous study we reported a comparable change/responsiveness 
in overall calf fat fraction (SRM 0.83) in a 12-month follow-up 
study in a cohort of patients with CMT1A.13
Assessments focusing on sensory impairment (sensory NCS, 
most of the QST parameters and IENFD) have been hampered 
by floor effects. Due to the variable episodic nature of the neuro-
pathic pain, another element of the condition, assessing longitu-
dinal change will be difficult, especially with many of the existing 
pain questionnaires capturing only short periods of time. Despite 
the name HSN1, we have shown that there is significant motor 
involvement with a consistent pattern of disease progression: 
early progressive sensory involvement followed later by progres-
sive motor involvement. The purpose of this study was to assess 
which of the potential outcome measures showed the largest 
effect size over 12 months across the whole cohort. This was 
calf muscle fat fraction. To translate this into responsiveness in a 
clinical trial, the intervention must be able to exert an effect on 
the outcome measure in question; which would be expected for 
intramuscular fat fraction unless the intervention only affected 
sensory pathways. This should be borne in mind when designing 
clinical trials, an intervention which did not slow the progres-
sion of intramuscular fat accumulation could not be considered 
a complete treatment, and we have shown that it is the most 
responsive measure of motor axonal loss.
The effect size can be increased further if we select patients 
with baseline overall calf muscle fat fraction of 5%–70% (20 
patients, 59% of MRI cohort), which doubles the responsiveness 
of overall calf muscle fat fraction (from SRM of 0.81 to 1.60). 
With this responsiveness, the number required in each study arm 
to detect a 50% reduction in disease progression is 25. This is 
a feasible number to be recruited for a clinical trial in the UK.
The minimum clinically significant difference31 in fat fraction 
is yet to be determined. It remains important to include overall 
disease severity scores such as the CMTNSv2 and patient-re-
ported outcome measures in a clinical trial to confirm the longi-
tudinal validity of change in MRI calf muscle fat fraction. We 
have assessed this over 4 years in CMT1A and initial analysis 
shows promising results.32 Further analysis of a more proximal 
slice in those patients with HSN1 with >70% FF at the analysed 
level and a more distal slice for those with <5% FF may result 
in higher responsiveness of MRI muscle fat fraction over the full 
range of disease severity.
In conclusion, this study highlights the marked clinical hetero-
geneity of patients with HSN1 which is mainly due to sex. Calf 
muscle fat fraction, Hand-PPT and computerised myometric 
assessments of ankle plantar flexion and ankle inversion/ever-
sion significantly changed over 1 year and correlated with 
disease severity, patient-reported health-related quality of life 
and disease duration. MRI determined calf muscle fat fraction is 
highly responsive and looks very promising as outcome measure 
to be included in therapeutic trials in HSN1.
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